QTORIN - (TOIVA)

October 15, 2026: Palvella Therapeutics (NASDAQ: PVLA) announced poster presentations at the PeDRA Annual Conference (October 15–17, 2026) featuring previously reported data plus new pediatric analyses for investigational QTORIN sirolimus topical gel 3.9%.

QTORIN rapamycin / Phase 3 SELVA: In children with microcystic lymphatic malformations, pediatric analyses highlighted improvements in overall disease severity and in a blinded combined lesion score assessing lesion height, vesicle appearance, and leaking/bleeding. Poster 036 will be presented October 15, 2026, 5:00–7:00 p.m.

QTORIN rapamycin / Phase 2 TOIVA: In previously treated children with cutaneous venous malformations, pediatric analyses highlighted improvements in overall disease severity and reductions in lesion bleeding. Poster 035 will be presented October 15, 2026, 5:00–7:00 p.m.

The company said QTORIN rapamycin could become the first FDA-approved therapy for both microcystic lymphatic malformations and cutaneous venous malformations, which it described as rare diseases with no FDA-approved therapies. The release also states QTORIN rapamycin remains investigational and references planned regulatory milestones including anticipated NDA timing and FDA review process, without giving specific dates.